PER-010-07已完成未知
A Double-Blind Comparative Multicenter Study Of The Efficacy And Safety Of Parecoxib IV/IM 40 Mg Vs Placebo On Reducing Opioids Consumption Following Submuscular Breast Augmentation Surgery
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- PFIZER S.A.,
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Female patients of any ethnicity 18 years of age or older.
- •2. The patient is postmenopausal, surgically sterile, or must be using adequate contraceptive methods.
- •3. The patient should weigh 50 to 120 kg.
- •4. The patient needs an elective transaxillary subpectoral augmentation mammoplasty.
- •5. The patient has given the responsible surgeon a written informed consent on the specific surgical procedure.
- •6. The pre-operative health of the patient must have a class I or II degree according to the physical condition classification of the ASA.
- •7. The patient must agree to remain in the hospital or clinic until at least 24 hours after the first dose of the study medication and complete the safety and pain assessments of the protocol at least 24 hours after administration of the medication. The first dose of medication is study.
- •8. The patient has given written informed consent before the start of this study.
排除标准
- •1. The patient has significant clinical signs and symptoms suggesting morbid kidney or liver conditions.
- •2. In addition to the transaxillary subpectoral augmentation mammoplasty, the patient will undergo any other surgery during the same procedure.
- •3. The patient has been a recipient of a kidney, liver or heart transplant.
- •4. The patient is being treated for any kind of infection or has clinical suspicion of infection.
- •5. The patient is currently receiving anticoagulants.
- •6. The patient has a coagulopathy, which in the opinion of the researcher is considered clinically significant.
- •7. The patient has a fever and / or an infection.
- •8. The patient has a history of active peptic ulceration, active dyspepsia, gastrointestinal, esophageal and gastric bleeding, or duodenal ulcer within one month before the screening evaluation.
- •9. The patient has a history of abuse of alcoholic, analgesic or narcotic substances within one month before the screening evaluation visit.
- •10. The patient has any cognitive dysfunction that could prevent her participation in the study or compliance with the procedures mandated by the protocol.
- •11. The patient has a history of clinically significant hypersensitivity to any NSAID, cyclooxygenase inhibitors, analgesics or sulfa drugs that have a cross-sensitivity with the medications used in this study.
- •12. The patient has a history of uncontrolled chronic disease, which could contraindicate participation in the study or confuse the interpretation of the results.
- •13. Chronic pain condition that requires chronic treatment and / or which may affect pain assessments or response to therapy.
- •14. The patient has a clinically and significantly reduced volume.
- •15. The patient used analgesics or other agents during the 4
- •hours that precede the procedure that could confuse the analgesic responses.
- •16. Within one year before the screening evaluation, the patient has been diagnosed with, treated for, or does not have remission of any cancer other than basal cell carcinoma.
- •17. The patient has received any investigational medication within one month prior to the administration of the study medication or is scheduled to receive any investigational drug other than parecoxib during the course of this study.
- •18. The patient has been previously admitted in this study.
- •19. Patients with a history of established ischemic heart disease, peripheral arterial disease and / or cerebrovascular disease, as well as subjects with prior coronary, carotid, cerebral, renal, aortic or peripheral arterial vasculature revascularization procedures.
- •20. Other chronic or acute severe medical or psychiatric conditions or abnormalities in laboratory tests that may increase the risk associated with participation in the trial or administration of the investigational product or that may interfere with the interpretation of trial results and , in the opinion of the researcher, could make the patient not appropriate to enter this trial.
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic ControlMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusType 2 Diabetes MellitusEUCTR2008-003640-11-EEMerck & Co., Inc.1,295
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in PediatricSubjects with Moderate to Severe Ulcerative Colitis.EUCTR2013-003032-77-PLAbbvie Deutschland GmbH & Co. KG93
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Ulcerative Colitis.lcerative colitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2013-003032-77-GBAbbVie Deutschland GmbH & Co. KG85
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic ControlMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusType 2 Diabetes MellitusEUCTR2008-003640-11-LVMerck & Co., Inc1,295
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in PediatricSubjects with Moderate to Severe Ulcerative Colitis.lcerative colitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2013-003032-77-ATAbbvie Deutschland GmbH & Co. KG101